It has surfaced the news that the CEO of SareptaTherapetics (NASDAQ:SRPT), Chris Garabedian, has been kicked to the curb by the company’s board of directors after his consistent urges to undertake a combative sort of relationship with the FDA.

With the CEO leading the company, many attempts had been taken on getting the drug Eteplirsen approved with just a few mid-stage trials being carried out along with a thorough follow up study. Initially, the FDA had tanked this idea back in November of 2013; however, afterwards, it made sure to delay the regulatory filing of the drug last October while citing any doubts of the company’s collection of data to estimate the dystrophin amount being used in production for the treatment of boys using the drug.

Afterwards, the CEO blamed everything on the FDA as it delayed the drug’s progress which caused somewhat of a riot. The relationship that the CEO had with the administration was a problematic one, which caused the board’s course to change altogether. The result was an extremely volatile price per share which has continued to fall for quite some time now.

It was stated in a press release that Ed Kaye, the company’s Chief Medical Officer, is going to replace the CEO but only for the interim period. The important thing to note here is that the company is still planning on submitting its drug for the approval of the FDA somewhere in the middle of the year.

So the question you might be asking right now is what investors should consider? The answer is pretty simple. If the drug is able to succeed in the regulator part of its journey then it can expect to ride a blockbuster roller coaster. This is the reason why a premium was paid by BioMarin (NASDAQ:BMRN) for its candidate of DMD and Prosensa in just the previous year even with the shaky sort of clinical profile that it had.

However, the problem is that DMD drugs have failed in trying to impress the six minute walk test which is a gold standard measurement in the clinical world. The problem was that patients who were treated with the therapies showed a huge range of variability for the measurement even with an increase in the dystrophin levels.

Therefore, the company has been lobbying the FDA ever since so that they may accept the production with dystrophin production just as a means to reach the end which could help in its approval. However, a workshop by the FDA that just took place showed the market that measuring the levels of dystrophin still remains a work-in-progress which shows the concerns that the agency has for the company’s clinical data.

It still remains doubtful that there will be an acceptance anytime soon by the FDA. However, on another note, the company was pretty good in walking stabilization when considering its intent to treat analysis at the 96^th week for patients using the drug.

Furthermore, Ford Motor Company (NYSE:F) has also been striving to increase both its top line and bottom line profits. The company’s stock has been directly influenced by this increase in its sales. There are speculations in the air that upcoming years hold a promise of much more profit for the company.

Ford Motor Company (NYSE:F) has been receiving considerable popularity and attention in China and consequently its sales also show an increase. This popularity of the company is particularly indebted to three of its models. These models are Escort, Mondeo, and the Ford Focus. Mondeo is also known as Fusion.

Statistics reflect that Ford Motor Company (NYSE:F) is China’s best-selling auto maker. For three years, the company has been receiving this award continually by the China Association of Automobile Manufacturers.

Other than these three models, there are three more models as well which have been receiving considerable popularity. These are Ford Mustang, Explorer and Edge. Statistics suggest that these three models have been responsible for increasing the company’s sales to about 18%. In January alone, an increase of 3000 units was observed in the total sales of these three models.

The sixth generation of the All-time-popular Ford Mustang has been the center of attention and anticipation in the Chinese automotive market. This model has made its way outside US for the first time. However, the car’s model has been modified a bit so that it can cope up with the requirements of the Chinese roads. Moreover, this is also done so that it becomes reasonable and affordable in almost 120 countries across the globe. It is speculated that v8 model of Mustang would soon become available in the Chinese markets.

Some cars tend to be a bit pricey in China, because importing them raises their prices. This increase in prices is directly proportional to the weight of the cars. Generally speaking, these two months have yielded maximum profits for the company and have proved to be more profitable than the entire year put together.

The financial results of January and February delineate sales of approximately 192,000 units. However, in comparison to the previous year, these figures reflect an increase of 15%.

The past years haven’t been really great for Ford Motor Company (NYSE:F) as it did make huge hits but then its pace slowed down. However, as a remedy to this situation, Ford Motor Company (NYSE:F) came up with its very first production facility of Chongqing. This facility would be able to produce approximately 360,000 units every year. The installation of this production facility would prove to be a great catalyst force for the company and would result in an increase in its sales carried out in the year 2015. Moreover, Ford Motor Company (NYSE:F) is also striving to establish such a facility in Hangzhou region, which will probably be culminated in the year 2016.

DJIA components Verizon Communications Inc. (NYSE:VZ) has a market capitalization of $205.9 billion,whereas the market capitalization of Coca-Cola Co. (NYSE:KO) is $177.5 billion. Facebook Inc. (NASDAQ:FB) has exceeded them already and has become greater than both of them.

There’s a huge difference between the balance sheets of Verizon Communications Inc. (NYSE:VZ) and Facebook Inc. (NASDAQ:FB) which has a longstanding debt of $110.5 billion. Verizon Communications Inc. (NYSE:VZ) has practically same amount of money and short-living investments. The point of differentiation comes at income and profits earned. Taking about Verizon Communications Inc. (NYSE:VZ), the earnings for the last year were calculated to be $127.1 billion with a total profit of $77.1 billion,for a perimeter of almost 61%. The functional perimeter reached 15.4% in comparison to 40% at Facebook Inc. (NASDAQ:FB).

Coca-Cola Co. (NYSE:KO) has an identical situation. It owes a longstanding debt of approximately $19 billion and short-living investments of almost $22 billion. The total income earned last year was calculated to be $46 billion with the addition of a profit found to be equal to $28.1 billion, for a perimeter of 61%. Working perimeter approached 21%.

All of these spending by Coca-Cola Co. (NYSE:KO)estimated to be $18.4 billion were transferred to SG&A the previous year. Facebook Inc. (NASDAQ:FB) paid out $2.7 billion on R&D as well as on SG&A. While Verizon Communications Inc. (NYSE:VZ) paid $41 billion on working expenditure in SG&A last year.

The major difference between these two old firms and Facebook Inc. (NASDAQ:FB) is because of the variation in their price to take possession, in the maintenance of physical assets, and giving out,and the price in winning distributing and in maintenance of a product, which will be manufactured once and supplied to uncountable users at practically incrementing no price.

Even though Facebook Inc. (NASDAQ:FB) has so many rivals, but the positive part is that it doesn’t have to pay a huge part of its earning for creating its new users by attracting them or any other way. Social media has this benefit of free network effects,while this is not the case in real-world limitations.These effects later result in income, profit and shareholder price along with development. The hoard price ofFacebookInc. (NASDAQ:FB) has increased up to 200% as compared to that of July, 2013. Whereas in contrast to this, Coca-Cola Co. (NYSE:KO) and Verizon Communications Inc. (NYSE:VZ) reduced to 0.5%.Both Coca-Cola Co. (NYSE:KO) and Verizon Communications Inc. (NYSE:VZ) will have to get into totally novel business at a considerable price while Facebook still has chances to develop.

However, just like all other pharmaceutical successes, Sovaldi draws in a lot of attention towards Gilead Sciences Inc. (NASDAQ:GILD). In the case of Gilead Sciences Inc., the heat comes from all those company that claim patents have been infringed by Gilead Sciences Inc. (NASDAQ:GILD) which they had registered for the creation of a hepatitis C drug. A recent case has brought Gilead Sciences Inc. (NASDAQ:GILD) in the spotlight yet again. This time, Sovaldi patent rights held by the company are been challenged by Idenix Pharamceuticals, a company which was recently acquired by Merck (NYSE:MRK).

Idenix Pharmaceuticals claims it already possessed patent rights to the Sovaldi drug way before the patent rights for the same acquired by Gilead Sciences Inc. (NASDAQ:GILD) Sovaldi is famous because it is a highly effective drug against Hepatitis C, and perhaps the most prescribed in Hepatitis C treatments. Whichever company holds patent rights to the drug is entitled to make it itself, and/or be entitled to royalties worth millions of dollars every year.

However, in a recent court batter between the two companies, Gilead Sciences Inc. (NASDAQ:GILD) blatantly crushed the case brought forward by Idenix Pharmaceuticals. The company argued that the patents held by Idenix Pharmaceuticals did not specify a compound directly aimed at a hepatitis drug, let alone Sovaldi.

The patents held by Idenix Pharmaceuticals, it was brought to light, covered billions of different compounds, one of which also happens to be the one used in Sovaldi. However, for a patent to stand, at least in the pharma business, it needs to specify the drug it is intended for. As Idenix Pharmaceuticals failed to specify which of its compound was for a hepatitis drug, it failed to defend its position in court. Gilead Sciences Inc. (NASDAQ:GILD) won the case.

However, this result is of the lawsuit fought in the UK. Idenix has challenged Gilead Sciences Inc. (NASDAQ:GILD) patents in Germany, Canada, and Australia, all throughout 2015. A court battle between Gilead Sciences and Idenix is also to be fought in France, but no particular date has been specified for it.

In the US, the drugs origins have been credited to Pharmasset, a company later bought by Gilead Sciences Inc., by the patent office in the US. However, Idenix is challenging this decision in a district court in the US.

Investors have responded favorably to the UK court’s decision regarding patent rights of the Sovaldi, because the hepatitis C drug formulates the backbone of the company’s business. Regardless of the decision in other courts all over the world regarding this particular case, investors seem to have regained confidence in the company, which is evident by the increase in its trading volume on the NASDAQ exchange.

Investors would definitely be focusing on CEO Mayer’s planning regarding utilization of Yahoo’s earnings from Alibaba’s initial public offering. They would also be focusing on the company’s actions for the growth of its core advertising businesses. According to a part of the agreement made in 2012, Yahoo traded part of its stakes in the Chinese company Alibaba and was able to generate in excess of $5 billion in cash from Alibaba IPO. As published in the Wall Street Journal, Yahoo (NASDAQ:YHOO) desires to procure one or more large technology start-ups spending some part of this money. Yahoo’s investors would not be favoring any move leading towards prospects of acquiring large entities due to the fact that turnaround strategy of Mayer is under close scrutiny after IPO of Alibaba (NYSE:BABA).

With the aim of enhancing shareholders value, Starboard Value hedge fund advised the CEO in September to stop acquisitions. They were also advised to reduce costs, explore chances of merger with AOL and increase the worth of Yahoo’s assets in Asia through better tax management.  However, it is expected that these suggestions would be confronted by Mayer. She would present her efforts towards cost reduction and would elaborate company’s processes while finalizing acquisitions. Ben Schachter an analyst with Macquarie Research indicated that the investor’s pressure would keep on mounting till the time Yahoo demonstrates long-term expansion in its core businesses. According to Schachter, obvious drivers for Yahoo’s (NASDAQ:YHOO) stock price are Alibaba’s cash and prospects for tax efficiency. Yahoo’s stock closed near $39 on Monday against the target of $40.

Mayer took over as Yahoo’s CEO two years back and even till this day she has not been able to achieve robust growth in the company’s core advertising businesses. Youssef Squali an analyst with Cantor Fitzgerald pointed out that for Yahoo 2013 was for right-sizing, investments and acquisitions. Whereas, monetization and growth revival goals for year 2014 are hard to achieve.

Yahoo (NASDAQ:YHOO) is expected to declare earnings of 30 cents per share o$1.05 billion revenue for third quarter, which is about 11 percent decline over the years on the bottom line and a 3 percent decline of top line.

RBC predicts that since Yahoo is facing stiff competition from Google (NASDAQ:GOOG) and others so there will be 7 percent decline in display revenue excluding traffic acquisition costs (ex-TAC). Yahoo’s last quarter performance was dismal as 8 percent decline to $436 million was reported. Besides Yahoo’s (NASDAQ:YHOO) search revenue has also shown signs of deceleration this year, the growth which stood at 9 percent in the first quarter was reduced to 6 percent (ex-TAC) in the second quarter and is estimated to grow by mere 4 percent in the third quarter.

1) Mortgage REITs are quite difficult to understand

Stability of dividends is a center point for Annaly (NYSE:NLY) whereas the company’s large expenditure has caused unstable dividends.

Security and Exchange commission wrote “You paid dividends of $1.6 million and had net cash used in operating activities of $12.9 million… please discuss the source(s) of these distributions… as this disparity raises concerns about the sustainability of distributions into the future.”

Unlike many other companies, Annaly (NYSE:NLY) has different priorities which works quite different from most real estate investor companies. The company (NYSE:NLY) gives off almost 90% taxed revenue to its stakeholders. So this results in dividends instead of cash.

2) Average debt issues

SEC quotes; “please tell us how you determined it was not necessary to continue to disclose… average amount of repurchase and reverse repurchase transactions”

Repurchase pacts are a kind of large scale borrowing deals, which are utilized for enhancing its investments. However, the simple rule of investment is the more you invest the greater are your chances for profit or loss. The company (NYSE:NLY) has large amounts of debts but usually tries to pay them around the end of every quarter. This somehow covers up Anally’s (NYSE:NLY) risk taking attitude.

An example of this strategy is the fact that Annaly’s (NYSE:NLY) annual debts were about 67 billion while the average figure was a staggering 91 billion. This gives us a little overview of the company’s (NYSE:NLY) overall performance.

3) Boosting up commercial equity levels:

The security and exchanges commission states that; “please tell us how you determined it was not necessary to provide… your commercial real estate debt.”

In Jan 2013 Annaly got an investment from “CreXus Investment” by making a triple net lease profile resulting in the leasing of real estates to a lot of different companies and firms. For more than 10 years the company (NYSE:NLY) had been investing in residential properties debt, but with this new addition the company has experienced a 180 degrees change.

So, we come to wonder the reason behind Annaly’s (NYSE:NLY) secretive behaviour, and to which the company’s CFO addresses that the commercial properties make only 2% only, which makes them less important to explain in greater detail.

The prominent points he added, “as [Annaly] intends to increase the size and proportion of the commercial real estate business, the company will provide the schedule in future 10-k filings.”

4) Liquidity of revenue

During Q2 the company (NYSE:NLY) claimed 96% of its total assets to be liquid which compensates for the company’s risk management level. However it turned out that only 12% are absolutely liquid while the remaining 88% is collateral. On this account the SEC stated that:

“Please tell us how you determined these items were liquid assets… how you determined it was appropriate to include and pledged investment securities within your liquid assets.”